A novel combinatorial strategy using Seliciclib registered and Belinostat registered for eradication of non-small cell lung cancer via apoptosis induction and BID activation

• Published in: Cancer letters Vol. 381; no. 1; pp. 49 - 57
• Main Authors: Ong, Pei-Shi, Wang, Lingzhi, Chia, Deborah Miao-Hui, Seah, Jolyn Yu-Xin, Kong, Li-Ren, Thuya, Win-Lwin, Chinnathambi, Arunachalam, Lau, Jie-Ying Amelia, Wong, Andrea Li-Ann, Yong, Wei-Peng, Yang, Daiwen, Ho, Paul Chi-Lui, Sethi, Gautam, Goh, Boon-Cher
• Format: Journal Article
• Language: English
• Published: 01.10.2016

With conventional anticancer agents for non-small cell lung cancer (NSCLC) reaching therapeutic ceiling, the novel combination using histone deacetylase inhibitor, PXD101 (Belinostat registered ), and CDK inhibitor, CYC202 (Seliciclib registered ), was investigated as an alternative anticancer strat...